Hi Toinv,

In my opinion, the webcast was much more informative than what appears from this discussion forum.

First, they announced that they would launch new molecules in order to avoid cannibalization - I think that the indications they are likely to be going for are to be found in the anti-inflammatory realm (>40 billion dollar market) - and they have in my opinion very good scientific reasons for going for such indications.

Second, they said they would announce a new deal. I tend to think that this will happen sooner than most people think, mainly because Resverlogix needs the money to pursue their new leads as well as launch their new trials, and I doubt that Resverlogix would have any difficulties making a deal anytime they want - the terms just need to be right.

Third, they proposed a small kidney dialysis study (20 patients). Results from such a trial could arrive a lot sooner than the BETonMACE trial data, and believe me, when looking at BET inhibitors, RVX-208 data and chronic kidney disease, RVX-208 stands out with a very convincing case.

I may be too optimistic, but upon listening and re-listening to the webcast, I actually got quite excited - a word that oddly enough was not used by DM ;-)

Best regards,

BKC

Disclaimer: This is not investment advice. Talk to a suitably certified advisor before making an investment in Resverlogix, as such an investment is extremely risky.